Christopher Autry
Pfizer
10 Papers
134 Citations
Christopher Autry is an academic researcher from Pfizer. The author has contributed to research in topics: Focal adhesion & PTK2. The author has an hindex of 6, co-authored 10 publications.
Chat about Author
Papers
Cellular characterization of a novel focal adhesion kinase inhibitor.
Jill K. Slack-Davis,Karen H. Martin,Robert W. Tilghman,Marcin P. Iwanicki,Ethan Ung,Christopher Autry,Michael Joseph Luzzio,Beth Cooper,John Charles Kath,W. Gregory Roberts,J. Thomas Parsons +10 more
TL;DR: P perturbation of adhesion-mediated signaling with a FAK inhibitor, PF-573,228, serves as a useful tool to dissect the functions of FAK in integrin-dependent signaling pathways in normal and cancer cells and forms the basis for the generation of compounds amenable for preclinical and patient trials.
483
Design of selective, ATP-competitive inhibitors of Akt.
Kevin Daniel Freeman-Cook,Christopher Autry,Gary Borzillo,Deborah A. Gordon,Elsa G. Barbacci-Tobin,Vincent Bernardo,David Briere,Tracey Clark,Matthew Corbett,John Jakubczak,Shefali Kakar,Elizabeth Knauth,Blaise Lippa,Michael Joseph Luzzio,Mahmoud N. Mansour,Gary J. Martinelli,Matthew A. Marx,Kendra Louise Nelson,Jayvardhan Pandit,Francis Rajamohan,Shaughnessy Robinson,Chakrapani Subramanyam,Liuqing Wei,Martin James Wythes,Joel Morris +24 more
TL;DR: This paper describes the design and synthesis of novel, ATP-competitive Akt inhibitors from an elaborated 3-aminopyrrolidine scaffold and finds an advanced analogue that performed well in advanced preclinical assays, including xenograft tumor growth inhibition studies, and was nominated for clinical development.
79
Trifluoromethylpyrimidine-based inhibitors of proline-rich tyrosine kinase 2 (PYK2): structure-activity relationships and strategies for the elimination of reactive metabolite formation.
Daniel P. Walker,F. Christopher Bi,Amit S. Kalgutkar,Jonathan N. Bauman,Sabrina X. Zhao,John R. Soglia,Gary Erik Aspnes,Daniel W. Kung,Jacquelyn Klug-McLeod,Michael P. Zawistoski,Molly A. McGlynn,Robert M. Oliver,Matthew F. Dunn,Jian-Cheng Li,Daniel Tyler Richter,Beth Cooper,John Charles Kath,Catherine Angela Hulford,Christopher Autry,Michael Joseph Luzzio,Ethan Ung,W. Gregory Roberts,Peter C. Bonnette,Leonard Buckbinder,Anil Mistry,Matthew C. Griffor,Seungil Han,Angel Guzman-Perez +27 more
TL;DR: Based on the proposed mechanism for bioactivation, as well as a combination of structure-based drug design and traditional medicinal chemistry techniques, a follow-up series of PYK2 inhibitors was identified that maintained PyK2 potency, FAK selectivity and HLM stability, yet were negative in the RM assay.
54
Patent
Sulfonyl amide derivatives for the treatment of abnormal cell growth
Michael Joseph Luzzio,Kevin Daniel Freeman-Cook,Samit Kumar Bhattacharya,Matthew Merrill Hayward,Catherine Angela Hulford,Christopher Autry,Xumiao Zhao,Jun Xiao,Kendra Louise Nelson +8 more
- 07 Apr 2008
TL;DR: In this paper, a method of using sulfonyl amide derivatives in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds is described.
49
Patent
Thienopyridine and thienopyrimidine anticancer agents
Matthew A. Marx,Michael Joseph Luzzio,Christopher Autry +2 more
- 20 Jun 2002
TL;DR: In this paper, the authors proposed a method for treating hyperproliferative disorders in a mammal by administering the compounds of formulas (1) and prodrugs thereof, pharmaceutically acceptable salts or solvates of said compounds or said pro-drugs, wherein X, R1 and R11 are as defined herein.
16